A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer
NCT00540358
Completed
The purpose of this clinical trial was to determine whether combining iniparib (BSI-201) with standard chemotherapy in estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer patients improve clinical benefit compared to treatment with standard chemotherapy alone. Based on data generated by BiPar/Sanofi, it was concluded that iniparib does not possess characteristics typical of the poly (ADP-ribo... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/21/2012
Locations: Research Site, Birmingham, Alabama +17 locations
Conditions: Breast Cancer
Register for Updates
Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma
NCT01182610
Terminated
This is an open-label, Phase II, single-stage study evaluating the use of panitumumab, paclitaxel, carboplatin and 5FU as an induction regimen in subjects with gastroesophageal adenocarcinoma. The expectation is that this combination will both increase potential overall survival by incorporating novel biologic therapy in the neoadjuvant setting and decrease potential surgical mortality by eliminating pre-operative radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2012
Locations: Clopton Clinic, Jonesboro, Arkansas
Conditions: Gastroesophageal Adenocarcinoma, Adenocarcinoma of the Distal Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Adenocarcinoma of the Proximal Stomach
Register for Updates
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
NCT00316173
Completed
This study was designed to find the most effective and safest doses of both HYCAMTIN and CARBOPLATIN that can be given for the treatment of ovarian cancer. This study may allow researchers to determine the effectiveness of combining HYCAMTIN and CARBOPLATIN.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/21/2012
Locations: GSK Investigational Site, Los Angeles, California +21 locations
Conditions: Ovarian Cancer, Neoplasms, Ovarian
Register for Updates
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
NCT00005051
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/08/2012
Locations: Albert Einstein Clinical Cancer Center, Bronx, New York +9 locations
Conditions: Ovarian Cancer
Register for Updates
Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors
NCT00002619
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow or peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by autologous bone marrow or peripheral stem cell transplantation in treating patients with glioblastoma multiforme or brain stem tumors.
Gender:
ALL
Ages:
Between 6 years and 59 years
Trial Updated:
11/08/2012
Locations: Kaplan Cancer Center, New York, New York
Conditions: Brain and Central Nervous System Tumors
Register for Updates
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00085501
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining more than one chemotherapy drug with a monoclonal antibody may kill more tumor cells. It is not yet known whether cetuximab is more effective when given at the same time a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2012
Locations: Alaska Regional Hospital, Anchorage, Alaska +162 locations
Conditions: Lung Cancer
Register for Updates
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
NCT01604863
Suspended
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or docetaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2012
Locations: Not set, Scottsdale, Arizona +1 locations
Conditions: Cancer
Register for Updates
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
NCT00482014
Completed
The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2012
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California +10 locations
Conditions: Non-Small-Cell Lung Cancer
Register for Updates
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
NCT00005798
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating women who have breast cancer.
Gender:
FEMALE
Ages:
Between 15 years and 64 years
Trial Updated:
10/24/2012
Locations: Halifax Medical Center, Daytona Beach, Florida +2 locations
Conditions: Breast Cancer
Register for Updates
Phase I Study of TAS-106 in Combo With Carboplatin
NCT00752011
Completed
The goal of this clinical research study is to find the highest safe dose of the combination of TAS-106 and carboplatin that can be given to patients with advanced cancer or cancer that has spread. Objectives: Primary Objectives: To determine the maximum tolerated dose (MTD) of the combination of TAS-106 and carboplatin administered by intravenous infusion every 3 weeks. To perform Pharmacokinetic (PK) analysis of TAS-106 and carboplatin Secondary objectives: To assess the antitumor activi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2012
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Cancer, Solid Tumors
Register for Updates
S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00003587
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of two different combination chemotherapy regimens in treating patients who have stage IIIB or stage IV non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2012
Locations: MBCCOP - University of South Alabama, Mobile, Alabama +83 locations
Conditions: Lung Cancer
Register for Updates
Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
NCT01300793
Terminated
Primary objective of the study is to determine the maximum tolerated dose (MTD) of bortezomib (Velcade) in combination with rituximab, ifosfamide, carboplatin and etoposide for adult patients with relapsed or refractory aggressive B-cell lymphoma. The secondary objectives are to assess the tolerability and safety, the response rate, rate of autologous stem cell transplant and CD34+ progenitor cell collection and engraftment after treatment with this regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2012
Locations: Unviersity of California Medical Center, San Francisco, California
Conditions: Non-Hodgkin's Lymphoma, B-cell Lymphoma
Register for Updates